Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
16 November 2023 - 10:00PM
Zealand Pharma Increases its Share Capital as a Consequence of
Exercise of Employee Warrants
Company announcement – No. 39 / 2023
Zealand Pharma Increases its Share Capital as a Consequence
of Exercise of Employee Warrants
Copenhagen, Denmark, November 16, 2023 – Zealand Pharma
A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a
Copenhagen-based biotechnology company focused on the discovery and
development of innovative peptide-based medicines, has increased
its share capital by a nominal amount of DKK 26,637 divided into
26,637 new shares with a nominal value of DKK 1 each. The increase
is a consequence of the exercise of warrants granted under several
of Zealand Pharma's employee warrant programs.
Employee warrant programs are part of Zealand Pharma’s incentive
scheme, and each warrant gives the owner the right to subscribe for
one newly issued Zealand Pharma share at a prespecified price, the
exercise price, in specific predefined time periods before
expiration. For a more detailed description of Zealand Pharma’s
warrant programs, see the company’s Articles of Association, which
are available on the website: www.zealandpharma.com.
The exercise price was DKK 127.00 per share for 9,119 of the new
shares, DKK 224.40 per share for 12,518 of the new shares and DKK
220.00 per share for 5,000 of new shares. The total proceeds to
Zealand from the capital increase amount to DKK 5,067,152.2.
The new shares give rights to dividend and other rights from the
time of the warrant holder's exercise notice. Each new share
carries one vote at Zealand Pharma’s general meetings. Zealand
Pharma has only one class of shares.
The new shares will be listed on Nasdaq Copenhagen after
registration of the capital increase with the Danish Business
Authority. Following registration of the new shares, the share
capital of Zealand Pharma will be nominal DKK 58,704,075 divided
into 58,704,075 shares with a nominal value of DKK 1 each.
A full copy of the amended Articles of Association can be found
at https://www.zealandpharma.com once registered with the Danish
Business Authority.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology
company focused on the discovery and development of peptide-based
medicines. More than 10 drug candidates invented by Zealand have
advanced into clinical development, of which two have reached the
market and three candidates are in late-stage development. The
company has development and partnerships with a number of blue-chip
pharma companies as well as commercial partnerships for its
marketed products.
Zealand was founded in 1998 and is headquartered in Copenhagen,
Denmark, with a presence in the U.S. For more information about
Zealand’s business and activities, please
visit www.zealandpharma.com.
Contacts:
Anna Krassowska, PhD Vice President, Investor Relations &
Corporate Communications Zealand PharmaEmail:
ank@zealandpharma.com |
|
Adam LangeInvestor Relations OfficerZealand PharmaEmail:
akl@zealandpharma.com |
Zealand Pharma AS (TG:22Z)
Historical Stock Chart
Von Mai 2024 bis Jul 2024
Zealand Pharma AS (TG:22Z)
Historical Stock Chart
Von Jul 2023 bis Jul 2024